Restaging [(18)F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance Journal Article

  

Authors:	Mahajan, S.; Barker, C. A.; Mauguen, A.; Singh, B.; Pandit-Taskar, N.
Article Title:	Restaging [(18)F] fludeoxyglucose positron emission tomography/computed tomography scan in recurrent cutaneous squamous cell carcinoma: Diagnostic performance and prognostic significance
Abstract:	Background: There are no specific recommendations for [18F] fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in assessing recurrent cutaneous squamous cell carcinoma (cSCC). Objective: To evaluate FDG-PET/CT in recurrent cSCC. Methods: FDG-PET/CT scans were retrospectively reviewed. Sites of abnormal uptake were noted and correlated with biopsy/histopathology studies, where available, and with follow-up imaging or clinical data in others. Comparison with available CT/magnetic resonance imaging was performed. The prognostic significance of PET/CT parameters was evaluated, and PET/CT-based change in management was recorded. Results: A total of 115 FDG-PET/CT scans were analyzed in 100 consecutive patients with cSCC. Of these, 96 (84%) scans were positive for recurrence, and 25 showed distant metastases. PET/CT detected unsuspected disease sites in 39 of 115 scans (34%), locoregional disease in 14, distant metastases in 11, both locoregional disease and distant metastases in 8, additional local cutaneous disease in 5, and second malignancy in 1. Comparison of 78 PET/CT scans with available CT/magnetic resonance imaging showed 37 additional abnormalities on 23 PET/CT scans, predominantly including skin/subcutaneous lesions and nodes. PET/CT led to change in management in 28% of patients. On univariate/multivariate analysis, increased number of FDG-positive lesions and lung metastases on PET/CT was associated with increased risk of death/disease progression. Limitations: Retrospective study. Conclusions: FDG-PET/CT was sensitive in detecting recurrent disease in cSCC, led to change in management for 28% of patients, and proved to be of prognostic value. © 2019 American Academy of Dermatology, Inc.
Keywords:	adult; cancer chemotherapy; controlled study; human tissue; treatment outcome; aged; primary tumor; major clinical study; overall survival; histopathology; cancer localization; cancer recurrence; squamous cell carcinoma; bone metastasis; cancer staging; nuclear magnetic resonance imaging; positron emission tomography; follow up; lymph node metastasis; antineoplastic agent; cancer diagnosis; neoplasm; image analysis; skin biopsy; oncology; retrospective study; distant metastasis; skin carcinoma; liver metastasis; lung metastasis; diagnostic value; cutaneous; fluorodeoxyglucose f 18; brain metastasis; second cancer; peritoneum metastasis; paranasal sinus cancer; pericardium; predictive value; chemoradiotherapy; muscle metastasis; recurrent; heart metastasis; restaging; fdg-pet/ct; ethmoid sinus; cancer prognosis; prognosis; human; male; female; priority journal; article; median survival time; positron emission tomography-computed tomography
Journal Title:	Journal of the American Academy of Dermatology
Volume:	82
Issue:	4
ISSN:	0190-9622
Publisher:	Mosby Elsevier
Date Published:	2020-04-01
Start Page:	878
End Page:	886
Language:	English
DOI:	10.1016/j.jaad.2019.09.035
PUBMED:	31562942
PROVIDER:	scopus
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85078530142&doi=10.1016%2fj.jaad.2019.09.035&partnerID=40&md5=021c3648a8cd3d3ab053d00ceb9e11c1
Notes:	Article -- Export Date: 1 April 2020 -- Source: Scopus